Background: In clinical trials, highly active antiretroviral therapy (HAART) reduces plasma
HIV-1 RNA levels to less than 500 copies/mL in 60% to 90% of patients with HIV-1 infection …

Objectives To ascertain whether prolonged suppression of viral replication can be achieved
in clinical practice and to identify factors associated with virological outcome. Design …

In this observational single-center cohort study outside the clinical trial setting, outcome and
predictors of virologic failure of highly active antiretroviral therapy (HAART) containing a …

Background: Mortality and morbidity related to AIDS have decreased among HIV-infected
patients taking highly active anti-retroviral therapy (HAART), but previous studies may have …

The outcome and predictors of virologic treatment failure of highly active antiretroviral
therapy (HAART) were determined for 271 human immunodeficiency virus (HIV)-infected …

Background: Combination antiretroviral therapy with protease inhibitors has transformed HIV
infection from a terminal condition into one that is manageable. However, the complexity of …

The availability of an increasing number of antiretroviral agents and the rapid evolution of
new information has introduced extraordinary complexity into the treatment of HIV-infected …

Many clinicians who care for patients with HIV infection are dissatisfied with the existing
recommendations on antiretroviral therapy. Current practice focuses on the early …

Background: Markers are needed for assessing response to antiretroviral therapy over time.
The CD4+ lymphocyte count is one such surrogate, but it is relatively weak. Objective: To …

Background Although the incidence of most AIDS events declines after initiation of highly
active antiretroviral therapy (HAART), this decline is more rapid for some conditions than …